Search
Clinician Ordering Portal
Scientific evidence
Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma
May 2018
Survey and clinical vingettes to determine the impact of three factors - Breslow thickness, ulceration, and sentinel lymph node biopsy status - on the decision to order the 31-GEP test.
Publication: Journal of Drugs and Dermatology
Prospective multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients
Mar 2018
Initital data from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits.
Publication: SKIN: Journal of Cutaneous Melanoma
Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients
Feb 2018
Study was designed to assess the analytical validity of the 31-GEP test.
Publication: Diagnostic Pathology
Guidelines of care for the management of cutaneous squamous cell carcinoma
Feb 2018
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC.
Publication: J Am Acad Dermatol
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients
Feb 2018
Multicenter study using GEP was used in combination with SLNB to enhance identification of patients with high-risk melanoma. GEP predicted additional recurrences and distant metastases, improving sensitivity over using SLNB alone.
Publication: BMC Cancer
Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging
Feb 2018
Assesed impact of GEP results on the management of clinically node negative cutaneous melanoma patients staged with sentinel lymph node biopsy (SLNB). 31-GEP was significantly associated with the management of stage I-II melanoma patients after staging with SLNB. Node negative Class 2 patients led to more aggressive management.
Publication: Journal of Drugs and Dermatology
Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
Jan 2018
Systems biology approaches in cancer pathology
Jan 2018
A method for objective quantification of epithelial and stromal biomarkers to generate a tissue profile aiding predictive models for cancer pathology.
Publication: Methods in Molecular Biology
Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility
Jan 2018
Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma
Dec 2017
Assessment of the sensitivity and specificity of 23-GEP in melanocytic lesions with a desmoplastic component.
Publication: Human Pathology
Economic evaluation of implementing a novel pharmacogenomic test (IDgenetix®) to guide treatment of patients with depression and/or anxiety
Nov 2017
The treatment of actinic keratoses — the rule rather than the exception
Nov 2017
This work highlights a critical aspect of the physician-patient relationship—communication. As expected, the findings suggest that the verbiage used to describe actinic keratoses (AKs) can affect the patient’s decision to pursue treatment. Interestingly, regardless of how the question was framed, most patients preferred to treat these lesions.
Publication: JAMA Dermatol